Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)
暂无分享，去创建一个
S. Swindells | Kimberly Smith | E. Overton | W. Spreen | D. Margolis | A. Mills | P. Benn | M. Shaefer | R. van Solingen-Ristea | S. Vanveggel | Yuanyuan Wang | Krischan J. Hudson | V. Chounta